The acetylation polymorphism is one of the most common genetic variations in the transformation of drugs and chemicals. More than 50% of individuals in Caucasian populations are homozygous for a recessive trait and are of the "slow acetylator" phenotype. They are less efficient than "rapid acetylators" in the metabolism of numerous drugs and environmental and industrial chemicals. The acetylation polymorphism is associated with an increased risk of drug toxicity and with an increased frequency of certain cancers. We report the identification of the primary mutations in two alleles of the gene for the N-acetyltransferase (NAT; acetyl-CoA:arylamine N-acetyltransferase, EC 2.3.1.5) isozyme NAT2 associated with slow acetylation. These alleles, Ml and M2, account for more than 90% of slow acetylator alleles in the European population we have studied. Ml and M2 were identified by restriction fragment length polymorphisms with Kpn I and Msp I and subsequently cloned and sequenced. Ml and M2 each are characterized by a combination of two different point mutations, one causing an amino acid substitution (Ile-113 -* Thr in Ml, Gin in M2), the other being silent (C 481 -+ T in Ml, C 282 T in M2). Functional expression of Ml and M2 and of chimeric gene constructs between mutant and wild-type NAT2 in COS-1 cells suggests that Ml causes a decrease of NAT2 protein in the liver by defective translation, whereas M2 produces an unstable enzyme. On the basis of the mutations described here and a rare mutant allele (M3) reported recently, we have developed a simple DNA amplification assay that allows the predictive genotyping of more than 95% of slow and rapid acetylator alleles and the identification of individuals at risk.
Ml, Arg-197 Gin in M2), the other being silent (C 481 -+ T in Ml, C 282 T in M2). Functional expression of Ml and M2 and of chimeric gene constructs between mutant and wild-type NAT2 in COS-1 cells suggests that Ml causes a decrease of NAT2 protein in the liver by defective translation, whereas M2 produces an unstable enzyme. On the basis of the mutations described here and a rare mutant allele (M3) reported recently, we have developed a simple DNA amplification assay that allows the predictive genotyping of more than 95% of slow and rapid acetylator alleles and the identification of individuals at risk.
The acetylation polymorphism is one of the most common inherited variations in the biotransformation of drugs and chemicals. Its association with drug toxicity and an increased risk to develop certain cancers has made it one of the oldest and best-studied examples of a pharmacogenetic condition (1) (2) (3) . Forty to 70% of Caucasians in Europe and North America are of the "slow acetylator" phenotype and are less efficient than "rapid acetylators" in the metabolism of numerous drugs and chemicals containing primary aromatic amine or hydrazine groups. These include agents such as isoniazid, sulfamethazine (SMZ) and other sulfonamides, procainamide, hydralazine, dapsone, and caffeine, as well as several chemicals with carcinogenic potential such as benzidine, 2-aminofluorene, and f-naphthylamine, present in dyes, antioxidants, pesticides, and explosives (2) (3) (4) . Highly mutagenic and carcinogenic arylamines also are generated during cooking of food (5) . Slow acetylators are at higher risk to develop bladder cancer (1) (2) (3) (4) , whereas rapid acetylators are at higher risk for colorectal cancer (6) .
In previous studies, we have shown that slow acetylators have a quantitative decrease in their liver of a cytosolic arylamine N-acetyltransferase (NAT; acetyl-CoA:arylamine N-acetyltransferase, EC 2.3.1.5) (7). This enzyme was purified (8) and two human genes, NAT] and NAT2, encoding two NAT proteins, were subsequently cloned and characterized (9, 10) . NAT2 was identified as the gene encoding the "polymorphic" NAT2 isozyme (10, 11) .
To study the molecular mechanism of slow acetylation, we have performed restriction fragment analysis with a NA72 probe on genomic DNA samples of individuals whose acetylator phenotype had been established. This led to the identification of two mutant alleles (Ml and M2), which account for over 90% of the alleles associated with slow acetylation. We describe the mutations in the Ml and M2 alleles and how they cause deficient NAT2 in livers of slow acetylators. On the basis ofthis information and the sequence of a rare NAT2 allele recently reported from Japan (12, 13), we have developed a simple allele-specific DNA amplification assay that allows the predictive genotyping of slow and rapid acetylators. METHODS Acetylator Phenotype. The acetylator phenotype was determined by measurement of the urinary molar ratio of the caffeine metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU) and 1-methylxanthine as described (14) , except that urine samples were acidified to pH 3.5 immediately after collection and stored frozen to ensure chemical stability of AFMU, and urine was extracted with 30 vol of 100% chloroform. Liver samples were from the human liver bank at the Biocenter in Basel (7) . The activity of NAT2 (in vitro phenotype) was determined with the substrate SMZ (7, 8 
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Cloning and Sequencing of Mutant NAN2 Alleles. Mutant allele Ml was isolated from a genomic library constructed in AEMBL3, using DNA from a heterozygous wild-type (wt)/M1 individual. A cDNA encoding the rabbit NAT2 enzyme (20) was used for screening. Details of the cloning of Ml are given in ref. 10 . For sequence analysis of Ml the 1.9-kilobase (kb) EcoRI fragments containing the single coding exon of NAT2 were isolated from 12 positive AEMBL3 clones and subcloned in pBluescript (Stratagene). M2 was cloned from DNA of a homozygous M2/M2 individual by screening of a AgtlO library constructed from EcoRI-digested genomic DNA after size selection (1.6-2.1 kb) on a 1% agarose gel. The 1.9-kb EcoRI fragment containing the wt NAT2 coding exon was used as hybridization probe and the inserts of positive phages were also subcloned in pBluescript. Sequences of Ml and M2 were determined by using the dideoxy chain termination method (21) and Sequenase (United States Biochemical).
Cloning of Chimeric NAT2 Gene Constructs. Chimeric constructs of wt and Ml and M2 alleles were generated by Xba I digestion of 1.9-kb EcoRI fragments harboring NAT2 coding exons, fragment isolation, and religation as indicated in Fig. 3 .
Functional Expression of NAT2 Alleles and Chimeric Constructs in Monkey Kidney COS-1 Cells. EcoRI fragments (1.9 kb) containing NAT2 coding exons were subcloned in the vector p91023 (B) (22) and transiently expressed in COS-1 cells as described (23) .
NAT Enzyme Assay and Immunoquantification of NAT2 on Western Blots. NAT2 enzyme activity was measured in cytosol from liver and from transfected COS-1 cell cultures by using SMZ as substrate. The NAT assay and the determination of kinetic parameters (Km, Vmax) were performed as described (7, 8) . Immunoreaction on Western blots used a polyclonal rabbit antiserum raised against purified human NAT2 (8). The serum was prepurified on nitrocellulose strips containing purified rabbit NAT2 (23, 24) . Blot intensities of NAT2-specific protein bands at 31 kDa were quantified by using a Camag (Muttenz, Switzerland) TLC scanner in the transmission mode.
Allele-Specific Amplification ofNAT2 Alleles. Specific primers for the wt and the mutant alleles Ml, M2 (this study), and M3 (12) were used in separate polymerase chain reactions (PCRs) (25) . Primer "Ml wt" (CTGATTTGGTCCAG) is complementary to the NAT2 gene at position 481-494, primer "Ml mut" (CTGATTTGGTCCAA) recognizes the mutation C 481 -* T of Ml; primers "M2 wt" (574-590, TTTACGCT-TGAACCTCG) and "M2 mut" (574-590, TTTACGCT-TGAACCTCA) test for the presence ofthe mutation G 590 -* A of M2, primer pairs "M3 wt" (857-870, AATAGTAAGG-GATC) and "M3 mut" (857-870, AATAGTAAGGGATT) for the mutation G 857 -* A (12) of M3. The common primer used for the reactions with primers Ml wt, Ml mut, M3 wt, and M3 mut is "primer 1" (-74 to -58, AATTAGTCACAC-GAGGA), for the reactions with primers M2 wt and M2 mut it is "primer 2" (1119-1138, TCTAGCATGAATCACTC-TGC).
All PCRs were carried out in a total volume of 50 ,ul in the presence of 10 (14) , and on DNA from 33 human liver samples with known NAT2 enzyme activity measured with the substrate SMZ (7). Hybridization and wash conditions were chosen so that NAT2-specific signals were 10-to 50-fold stronger than signals derived from the two related human genes NAT] and NATP, which share 87% and 79o nucleotide identity with NAT2 (10). RFLPs generated by Msp I and Kpn I segregated with acetylator phenotype; for simplicity and because Msp I detected only one mutant allele (Ml), only Kpn I RFLPs are shown in Fig. la In both Ml and M2 a point mutation causing a single amino acid change in the deduced protein sequence was combined with an additional silent base substitution (Fig. lb) . The silent mutation in Ml alters the recognition sequence for the (Fig. 2b) . Impaired translation of mutant mRNA and more rapid degradation of the mutant t o NAT2 protein were therefore considered as potential mechanisms leading to these results. They were tested by functional expression of wt and mutant alleles in monkey kidney COS-1 cells (Fig. 3) , using the expression vector p91023(B) (22 Medical Sciences: Blum et al.
Functional Significance of the Mutations in Ml and M2. To dissect the contribution of single mutations, the chimeric gene constructs schematically depicted in Fig. 3d were analyzed by transient expression as described above. Constructs Cl and C2, each bearing only one of the two mutations of allele Ml, on expression both behaved like the normal enzyme, demonstrating that both nucleotide substitutions of Ml are required to decrease enzyme protein. Analysis of the M2-derived constructs C3 and C4 showed that the silent mutation alone (C3) results in wt behavior and that it is the amino acid change Arg-197 --Gln (C4) which causes the reduction of enzyme protein. In agreement with these results, the construct C5, which carries the two mutations causing amino acid changes of Ml and M2, led to decreased protein and function, whereas the product of C6, which contains the silent mutations of Ml and M2, was indistinguishable from that of the wt gene. We then compared the stabilities of expressed proteins and found that the half-lives at 370C of wt and Mi-derived activities were identical (22 hr), whereas that of M2 was reduced to 6 hr. Thus, the Arg-197 --Gln mutation of M2 apparently produces a less stable protein, whereas the combination of the two nucleotide substitutions in Ml presumably causes defective translation. Obviously, the mechanism by which Ml and M2 cause decreased NAT2 will have to be further studied.
Predictive Genotyping Test by Allele-Specific Ampliflication.
The knowledge of the mutations of Ml and M2, as well as that of a third mutant allele, M3, recently reported by Ohsako and Deguchi (12) , was used to develop a set of mutation-specific primers for allele-specific amplification of small amounts of DNA by the PCR (Fig. 4) . The study population was composed of 18 phenotyped individuals in vivo [caffeine test (14) ] and of 26 liver samples phenotyped in vitro [SMZ acetylation (7) ]. Twenty-four were classified as slow and 20 as rapid acetylators. Our test predicted correctly 19 of the 20 rapid and 22 of the 24 slow acetylator phenotypes. Of the 65 slow alleles identified, Ml accounted for 30 alleles (46%), M2 for 32 alleles (49%), and M3 for only 3 alleles (5%).
DISCUSSION
In the present report we provide evidence that "slow acetylation" in humans is due to mutations in the single coding exon of the NAT2 gene, one of two closely related genes on chromosome 8 recently characterized in this laboratory (10 Two mutant alleles, Ml and M2, were identified by RFLPs and cloned and sequenced. They account for the majority or >90% of slow acetylator alleles, and on expression in COS-1 cells they cause the marked decrease of NAT2 protein previously observed in livers of slow acetylators (7) .
The experiments with expression of wt and mutant NA72 genes described in Fig. 3 resolve the old controversy on whether slow acetylation is caused by a quantitative decrease of a functionally normal enzyme (26) , or the presence of a functionally altered enzyme (27) . According to our results, slow acetylation in humans is due to the quantitative decrease of an enzyme protein with a substrate affinity identical to that of the wt enzyme (Fig. 3) .
The analysis of chimeric constructs between wt, Ml, and M2 in COS-1 cells gives first insights on how the individual mutations are causing the decrease in NAT2. In the case of Ml, both the mutation causing an amino acid change and the silent base substitution are required to result in decreased protein and consequently decreased activity. We assume that translation of mutant mRNA is impaired, possibly by an alteration in mRNA secondary structure. In contrast to Ml, the one mutation causing an amino acid change in M2 is sufficient to cause the mutant phenotype, and the analysis of the expressed protein suggests that it is less stable than the wt and Ml derived enzymes.
The molecular mechanism of slow acetylation in humans is fundamentally different from that of the widely used animal model, the New Zealand White rabbit (28), where we have observed that a deletion causes the total absence of the NAT2 protein (23) .
A recent study from Japan (12, 13) described M2 and a third mutant allele, M3, by RFLP analysis. A point mutation (G 857 --A) in M3 was reported by these investigators (12 (6) . The described DNA assay will permit a careful reexamination of this large body of clinical observations. It allows the prediction of the acetylator phenotype in over 95% of individuals tested and requires only a small sample of DNA, which may be derived from leukocytes, single hair roots, buccal epithelia, or any other tissue. This will allow the genotyping of patients and volunteers in clinical studies or of workers at high risk on exposure to arylamine chemicals.
